TELA Bio director awarded 6,227 stock shares

Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.

TELA Bio, Inc. director Joseph H. Capper received a grant of 6,227 shares of common stock on 2026-07-15. The shares were issued in lieu of cash compensation under the company’s Amended and Restated Non-Employee Director Compensation Policy and are fully vested. Following this grant, Capper directly owns 29,827 shares of TELA Bio common stock.

Insider Trade Summary

Grant/Award: 6,227 shares

Grant/Award 1 txn

Insider Capper Joseph H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	6,227	$0.785	$5K

Holdings After Transaction: Common Stock — 29,827 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock issued in lieu of cash compensation under the Issuer's Amended and Restated Non-Employee Director Compensation Policy. All shares are fully vested.

Key Figures

Shares granted: 6,227 shares Grant price: $0.785 per share Post-transaction holdings: 29,827 shares +2 more

5 metrics

Shares granted 6,227 shares Common stock grant to director Joseph H. Capper on 2026-07-15

Grant price $0.785 per share Reference value for the 6,227-share common stock grant

Post-transaction holdings 29,827 shares Total TELA Bio common stock directly owned by Capper after the grant

Vesting status 100% fully vested All shares in the 6,227-share grant are fully vested upon issuance

Transaction date 2026-07-15 Date of the reported common stock grant to the director

Key Terms

Amended and Restated Non-Employee Director Compensation Policy, in lieu of cash compensation, fully vested, grant, award, or other acquisition

4 terms

Amended and Restated Non-Employee Director Compensation Policy financial

"under the Issuer's Amended and Restated Non-Employee Director Compensation Policy"

in lieu of cash compensation financial

"Represents shares of common stock issued in lieu of cash compensation"

fully vested financial

"All shares are fully vested"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TELA (TELA) director Joseph H. Capper report?

Joseph H. Capper reported receiving a grant of 6,227 shares of TELA Bio common stock. The shares were issued as equity compensation for board service, not through an open-market purchase or sale, and are fully vested upon issuance.

How many TELA Bio (TELA) shares were granted to Joseph H. Capper and at what price?

Joseph H. Capper was granted 6,227 shares of TELA Bio common stock at a reference value of $0.785 per share. This equity award was provided instead of cash compensation under the company’s non-employee director compensation policy.

What is Joseph H. Capper’s total TELA Bio (TELA) share ownership after this grant?

After the reported grant, Joseph H. Capper directly owns 29,827 shares of TELA Bio common stock. This total reflects his holdings immediately following the 6,227-share award reported for the transaction dated July 15, 2026.

Were the TELA Bio (TELA) shares granted to Joseph H. Capper immediately vested?

Yes. All 6,227 shares of TELA Bio common stock granted to Joseph H. Capper are described as fully vested. This means there is no additional vesting schedule attached to this particular equity compensation grant.

Was Joseph H. Capper’s TELA Bio (TELA) equity grant made under a Rule 10b5-1 trading plan?

The report indicates the Rule 10b5-1 checkbox was not marked as an affirmative plan. The transaction is described as a compensation-related grant of fully vested shares in lieu of cash, not as part of a pre-arranged trading program.

What is the nature of the compensation behind Joseph H. Capper’s TELA Bio (TELA) share grant?

The 6,227-share grant represents shares of common stock issued in lieu of cash compensation under TELA Bio’s Amended and Restated Non-Employee Director Compensation Policy, providing equity instead of paying the director in cash for board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Capper Joseph H

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		6,227(1)	A	$0.785	29,827	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of cash compensation under the Issuer's Amended and Restated Non-Employee Director Compensation Policy. All shares are fully vested.

	/s/ Megan Smeykal, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)